Prevention of ovarian cancer by administration of progestin products
First Claim
Patent Images
1. A method for reducing the risk of ovarian cancer in a post-menopausal female subject in need thereof who is no longer ovulating comprising administering to the post-menopausal female subject a progestin product sensitive to reducing the risk of ovarian cancer in an amount effective to inhibit the conversion of non-normal, non-neoplastic ovarian epithelial cells of the female subject to neoplastic cells.
0 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to methods for preventing the development of epithelial ovarian cancer by administering progestin products, either alone or in combination with other agents such as estrogen products.
-
Citations
11 Claims
- 1. A method for reducing the risk of ovarian cancer in a post-menopausal female subject in need thereof who is no longer ovulating comprising administering to the post-menopausal female subject a progestin product sensitive to reducing the risk of ovarian cancer in an amount effective to inhibit the conversion of non-normal, non-neoplastic ovarian epithelial cells of the female subject to neoplastic cells.
- 4. A method for reducing the risk of ovarian cancer in a post-menopausal female subject in need thereof who is no longer ovulating comprising administering to the post-menopausal female subject a progestin product sensitive to preventing ovarian cancer in an amount effective to inhibit the conversion of non-normal, non-neoplastic ovarian epithelial cells of the female subject to neoplastic cells.
- 6. A method for reducing the risk of ovarian cancer comprising administering a pharmaceutical composition to a post-menopausal female subject in need thereof who is no longer ovulating, said composition comprising a progestin product sensitive to reducing the risk of ovarian cancer in an amount effective to inhibit the conversion of non-normal, non-neoplastic ovarian cells to neoplastic cells.
- 9. A method for reducing the risk of ovarian cancer comprising administering a pharmaceutical composition to a female subject in need thereof who is no longer ovulating, said composition comprising a progestin product sensitive to reducing the risk of ovarian cancer in an amount effective to increase apoptosis in non-normal ovarian epithelial cells of the female subject.
Specification